Abstract: The present invention provides phosphonate compounds and methods of preparing the phosphonate compounds so as to allow, for example, increased capability to modify nanoparticles for targeted drug delivery applications.

Abstract: Methods for producing stabilized solid dosage form pharmaceutical compositions are provided. In particular, methods for preparing protected granules containing morphinans, and solid dosage form pharmaceutical compositions produced using the morphinan-protected granules are provided.

Abstract: The present invention provides a process for preparing a saturated 6,14-dihydroxy morphinan. The process comprises contacting an unsaturated 6-O-hydrocarbyl morphinan with hydrogen peroxide and an organic acid to form an unsaturated 6-keto-14-hydroxy morphinan. The unsaturated 6-keto-14-hydroxy morphinan is contacted with a first reducing agent to form an unsaturated 6,14-dihydroxy morphinan, and the unsaturated 6,14-dihydroxy morphinan is contacted with a second reducing agent to form the saturated 6,14-dihydroxy morphinan.

Abstract: The invention relates generally to optical agents, including phototherapeutic agents, for biomedical applications, including phototherapy. The invention includes optical agents, and related therapeutic methods, comprising alicyclic diaza compounds, including 1,2 diaza heterocyclic compounds, having a photolabile N—N bond directly or indirectly linked to at least one carbocyclic aromatic and/or heterocyclic aromatic group. In some embodiments, for example, the invention provides alicyclic diaza compounds for phototherapeutic methods having a photolabile N—N bond that undergoes photoactivated cleavage to produce reactive species, such as radicals, ions, etc., that achieve a desired therapeutic effect, such as selective and/or localized tissue damage and/or cell death.

Abstract: The present invention provides substituted berbines, processes for the synthesis of substituted berbine compounds, as well as intermediates used in the synthesis of substituted berbine compounds. Also provided are methods for using the substituted berbines to inhibit cancer cell growth.

Abstract: A contrast media injection system includes detects the absolute position of the syringe ram using a non-contact sensor. A series of magnets and Hall-Effect sensors may be used or an opto-reflective system. Illuminated knobs that are connected to the drive mechanism for the syringe ram rotate with the drive and provide visual feedback on operation through the illumination. Analog Hall-Effect sensors are used to determine the presence or absence of magnets that identify the type of faceplate being used. The faceplates include control electronics, connected to the powerhead through connectors, which may be interchangeably used by the two faceplates. The faceplate electronics include detectors for automatically detecting the capacity of pre-filled syringes.

Abstract: The present invention relates generally to a sterile hydromorphone hydrochloride solution that is substantially free of buffer.

Abstract: A protective shroud is provided for covering a radiation shield that surrounds a nuclear pharmacy generator. The radiation shield includes components having seams therebetween. The protective shroud includes a tubular body configured to contain the radiation shield, a first opening adapted for receiving the radiation shield, and a second opening for allowing access into the radiation shield.

Abstract: A leak testing system (210) for medicament sachets (200) is disclosed. The system (210) includes a base section (220) having a flat surface (226). A plurality of guide rods (230) extend from this flat surface (226) of the base section (220). A press section (240) incorporates a plurality of through-holes (242) that are used to movably mount the press section (240) on the noted guide rods (230). The press section (240) includes a flat surface (246) that is maintained in at least substantially parallel relation to the flat surface (226) of the base section (220). A medicament pouch (200) may be compressed between these flat surfaces (226, 246) of the base section (220) and the press section (240) by sliding the press section (240) along the guide rods (230) and in the direction of the base section (240). Multiple press plates can be added to adjust the force and weight to test for leaks.

Abstract: The present invention provides processes for preparing normorphinans from N-substituted morphinans. In particular, the invention provides methods for removing the N-substituent from the N-substituted morphinan to from a normorphinan carbamate, and then removing the carbamate functionality from the normorphinan carbamate to form the normorphinan.

Abstract: A pharmaceutical product supply is disclosed in the form of a container, a pharmaceutical product receiver, pharmaceutical product, an adhesive, and at least one release liner. The pharmaceutical product receiver includes a plurality of receptacles for pharmaceutical product. The container is initially disposed in a first configuration where all of the pharmaceutical product receiver receptacles may be accessible. The container is thereafter disposable in a second configuration where no covering for any of the pharmaceutical product receiver receptacles is accessible through any openable access incorporated by the container. One or more release liners may be moved to expose adhesive for disposing and retaining the container in its second configuration. The noted second configuration of the container facilitates disposal of the pharmaceutical product supply (e.g.

Abstract: A power injector that incorporates at least one signal transmission connector in a movable joint (e.g., between a powerhead and a support or stand; between at least one adjacent pair of support sections of a support for the powerhead) is disclosed. Such a signal transmission connector may be in the form of a slip ring module, but in any case is part of the signal transmission link to the powerhead. At least that portion of a signal transmission conduit that is adjacent to the powerhead may be disposed within the interior of the corresponding portion of the support or stand, thereby reducing the potential that an individual will grab onto the signal transmission conduit when attempting to move at least part of the power injector, to change the position of the powerhead, or both.

Abstract: The present disclosure provides extended release pharmaceutical compositions comprising oxycodone and acetaminophen that produce a quick initial onset of analgesia, yet, maintain analgesia for about 12 hours after administration of the composition to a subject in need thereof. The pharmaceutical compositions disclosed herein also reduce the levels of acetaminophen in a subject's blood near the end of the dosing interval because the acetaminophen released by the pharmaceutical composition is being eliminated by a subjects body faster than it is being absorbed.

Abstract: Systems and methods for managing use of a pharmaceutical product are provided. The systems and methods utilize an external cover and a container, along with a first material and a pharmaceutical product that are each contained within an internal space that exists when the external cover is in a closed position relative to the container. Release of the first material may bond the external cover to the container, may result in the first material coming into contact with the pharmaceutical product, or both.

Abstract: The present invention provides processes for the preparation of saturated ketone morphinan compounds. In particular, the invention provides processes for the conversion of a morphinan comprising an allyl alcohol ring moiety into a morphinan comprising a saturated ketone ring moiety by an isomerization reaction catalyzed by an inorganic salt of a late transition metal.

Abstract: An improved process for the N-alkylation of tertiary morphinan alkaloid bases to form the corresponding quaternary morphinan alkaloid derivatives.

Abstract: A radioisotope elution system including a radioisotope generator having an alignment structure. The alignment structure may be configured to interface with a complementary alignment structure of an auxiliary radiation shield assembly.

Abstract: Contrast administration data that relates to operation of a contrast media injector system (602) may be converted from at least one format (e.g., a CAN-compliant format) to at least one other format (e.g., an HL-7-compliant format) by an injection data management module (660) for use by a medical system (600). Data on contrast media prescribed for an imaging operation using an imaging system (690), contrast media data for use in this imaging operation, and data on contrast media actually administered/injected by a contrast media injector system (602) for this imaging operation may be stored in a data structure (780) on the injection data management module (660). Patient renal function data may be used to control the dispensing of contrast media from a contrast media/storage/dispensing unit (500), to control the operation of the contrast media injector system (602), or both, and may be stored in the data structure (780) as well.

Abstract: Chelators of the formulae (I), (II) and (III) and tricarbonyl complexes of radioisotopes of Tc and Re bound to them, for use in myocardial imaging.

Abstract: Pharmaceutical product dispensers (e.g., in the shape of a common ink pen) are operable to indicate information regarding a dosing schedule of a pharmaceutical product dispensable from the dispenser. Embodiments of the dispensers may include a plurality of dosing segments, each corresponding to a different dose of the pharmaceutical product. Actuation of an actuator may result in interaction between the actuator and the pharmaceutical product storage area such that a dose of pharmaceutical product contained in the pharmaceutical product storage area is dispensed, along with a corresponding advancement of the plurality of dosing segments. The dispenser may also include one or more locks to prevent unauthorized access to the pharmaceutical product (e.g., by a child or the like). Furthermore, the pharmaceutical product dispenser may include a disabling mechanism to permanently disable actuation of the actuator of the dispenser.